Cutaneous B-cell lymphoma with loss of CD20 immunoreactivity after rituximab therapy

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Background: Antibodies to the B-cell-specific antigen CD20 are widely used for immunohistochemical identification of B-cell lymphomas, approximately 95% of which are strongly CD20-positive. Methods: We report a 51-year-old male with a CD20-positive systemic B-cell lymphoma who developed a CD20-negative relapse with secondary cutaneous involvement after therapy with the anti-CD20 monoclonal antibody rituximab (Rituxan). Results: Biopsy of a skin nodule demonstrated an atypical lymphocytic infiltrate that was negative for CD20, CD3, lysozyme, and myeloperoxidase, but strongly positive for CD45rb (LCA) and the B-cell marker CD79a. Conclusions: We conclude that loss of CD20 expression in cutaneous B-cell lymphoma (both primary and secondary) is important to recognize, that immunohistochemistry for CD79a, another widely expressed B-cell marker, is useful in the identification of CD20-negative B cells in such cases, and that loss of CD20 expression may become more common, as use of rituximab is expected to increase.

Original languageEnglish (US)
Pages (from-to)459-462
Number of pages4
JournalJournal of Cutaneous Pathology
Volume30
Issue number7
DOIs
StatePublished - Aug 1 2003

Fingerprint

B-Cell Lymphoma
B-Lymphocytes
Skin
CD20 Antigens
Therapeutics
Muramidase
Peroxidase
Immunohistochemistry
Monoclonal Antibodies
Biopsy
Recurrence
Rituximab
Antibodies

All Science Journal Classification (ASJC) codes

  • Pathology and Forensic Medicine
  • Histology
  • Dermatology

Cite this

@article{a810f4ab128d4290a9e4d04376037e60,
title = "Cutaneous B-cell lymphoma with loss of CD20 immunoreactivity after rituximab therapy",
abstract = "Background: Antibodies to the B-cell-specific antigen CD20 are widely used for immunohistochemical identification of B-cell lymphomas, approximately 95{\%} of which are strongly CD20-positive. Methods: We report a 51-year-old male with a CD20-positive systemic B-cell lymphoma who developed a CD20-negative relapse with secondary cutaneous involvement after therapy with the anti-CD20 monoclonal antibody rituximab (Rituxan). Results: Biopsy of a skin nodule demonstrated an atypical lymphocytic infiltrate that was negative for CD20, CD3, lysozyme, and myeloperoxidase, but strongly positive for CD45rb (LCA) and the B-cell marker CD79a. Conclusions: We conclude that loss of CD20 expression in cutaneous B-cell lymphoma (both primary and secondary) is important to recognize, that immunohistochemistry for CD79a, another widely expressed B-cell marker, is useful in the identification of CD20-negative B cells in such cases, and that loss of CD20 expression may become more common, as use of rituximab is expected to increase.",
author = "Clarke, {Loren E.} and Michael Bayerl and Ehmann, {W. Christopher} and Klaus Helm",
year = "2003",
month = "8",
day = "1",
doi = "10.1034/j.1600-0560.2003.00078.x",
language = "English (US)",
volume = "30",
pages = "459--462",
journal = "Journal of Cutaneous Pathology",
issn = "0303-6987",
publisher = "Wiley-Blackwell",
number = "7",

}

Cutaneous B-cell lymphoma with loss of CD20 immunoreactivity after rituximab therapy. / Clarke, Loren E.; Bayerl, Michael; Ehmann, W. Christopher; Helm, Klaus.

In: Journal of Cutaneous Pathology, Vol. 30, No. 7, 01.08.2003, p. 459-462.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Cutaneous B-cell lymphoma with loss of CD20 immunoreactivity after rituximab therapy

AU - Clarke, Loren E.

AU - Bayerl, Michael

AU - Ehmann, W. Christopher

AU - Helm, Klaus

PY - 2003/8/1

Y1 - 2003/8/1

N2 - Background: Antibodies to the B-cell-specific antigen CD20 are widely used for immunohistochemical identification of B-cell lymphomas, approximately 95% of which are strongly CD20-positive. Methods: We report a 51-year-old male with a CD20-positive systemic B-cell lymphoma who developed a CD20-negative relapse with secondary cutaneous involvement after therapy with the anti-CD20 monoclonal antibody rituximab (Rituxan). Results: Biopsy of a skin nodule demonstrated an atypical lymphocytic infiltrate that was negative for CD20, CD3, lysozyme, and myeloperoxidase, but strongly positive for CD45rb (LCA) and the B-cell marker CD79a. Conclusions: We conclude that loss of CD20 expression in cutaneous B-cell lymphoma (both primary and secondary) is important to recognize, that immunohistochemistry for CD79a, another widely expressed B-cell marker, is useful in the identification of CD20-negative B cells in such cases, and that loss of CD20 expression may become more common, as use of rituximab is expected to increase.

AB - Background: Antibodies to the B-cell-specific antigen CD20 are widely used for immunohistochemical identification of B-cell lymphomas, approximately 95% of which are strongly CD20-positive. Methods: We report a 51-year-old male with a CD20-positive systemic B-cell lymphoma who developed a CD20-negative relapse with secondary cutaneous involvement after therapy with the anti-CD20 monoclonal antibody rituximab (Rituxan). Results: Biopsy of a skin nodule demonstrated an atypical lymphocytic infiltrate that was negative for CD20, CD3, lysozyme, and myeloperoxidase, but strongly positive for CD45rb (LCA) and the B-cell marker CD79a. Conclusions: We conclude that loss of CD20 expression in cutaneous B-cell lymphoma (both primary and secondary) is important to recognize, that immunohistochemistry for CD79a, another widely expressed B-cell marker, is useful in the identification of CD20-negative B cells in such cases, and that loss of CD20 expression may become more common, as use of rituximab is expected to increase.

UR - http://www.scopus.com/inward/record.url?scp=0043168018&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0043168018&partnerID=8YFLogxK

U2 - 10.1034/j.1600-0560.2003.00078.x

DO - 10.1034/j.1600-0560.2003.00078.x

M3 - Article

VL - 30

SP - 459

EP - 462

JO - Journal of Cutaneous Pathology

JF - Journal of Cutaneous Pathology

SN - 0303-6987

IS - 7

ER -